GSK and SK bioscience's COVID vaccine submitted for S.Korea approval

Health News Comments Off on GSK and SK bioscience's COVID vaccine submitted for S.Korea approval
FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo

(Reuters) – GlaxoSmithKline’s (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday.

GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world.

The company said an extended clinical trial is planned to test the vaccine’s effectiveness against the Omicron variant of the virus.

Source: Read Full Article

Related posts:
  1. An Active Sex Life May Reduce Risk of Early Menopause
  2. AstraZeneca: Shot will be effective against COVID-19 variant
  3. \u2018I\u2019m a Critical Care Nurse, and I Just Received Pfizer’s COVID-19 Vaccine\u2019
  4. Sweeteners can the spread of antibiotic resistance, healing practice to accelerate
  5. Mindfulness training reduces chance of unnecessary cesareans
  6. Disparities in breast cancer care quality have reduced across Scotland
  7. Can you get the booster if you have a cold? 2 symptoms that could indicate Omicron